Bifidobacterium breve M-16V as a Probiotic for Preterm Infants: A Strain-Specific Systematic Review

Journal of Parenteral and Enteral Nutrition

Volumn 42, Issue 4, 2018, Pages 677-688

  Athalye Jape, Gayatri ^a,b,c   Rao, Shripada ^a,b,c   Simmer, Karen ^a,c   Patole, Sanjay ^a,c  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bifidobacterium breve; meta analysis; necrotizing enterocolitis; preterm infants; systematic review

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; CLINICAL OUTCOME; HUMAN; INFANT; INFANT MORTALITY; META ANALYSIS; NECROTIZING ENTEROCOLITIS; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW; NEWBORN; NEWBORN DISEASE;

BIFIDOBACTERIUM BREVE; ENTEROCOLITIS, NECROTIZING; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; PROBIOTICS; SEPSIS;

EID: 85042908018     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/0148607117722749     Document Type: Review

References (57)

1. Food and Agriculture Organization, World Health Organization. Guidelines for the evaluation of probiotics in food. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf. Published December 7, 2006.
2. Aceti A, Gori D, Barone G, et al. Italian Society of Neonatology. Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. Ital J Pediatr. 2015;41:89.
3. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014;(4):CD005496.
4. Lau CS, Chamberlain RS. Probiotic administration can prevent necrotizing enterocolitis in preterm infants: a meta-analysis. J Pediatr Surg. 2015;50(8):1405-1412.
5. Yang Y, Guo Y, Kan Q, Zhou XG, Zhou XY, Li Y. A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med Biol Res. 2014;47(9):804-810.
6. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921-930.
7. Rao SC, Athalye-Jape GK, Deshpande GC, Simmer KN, Patole SK. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics. 2016;137(3):e20153684.
8. Aceti A, Gori D, Barone G, et al. Probiotics and time to achieve full enteral feeding in human milk-fed and formula-fed preterm infants: systematic review and meta-analysis. Nutrients. 2016;8(8):E471.
9. Athalye-Jape G, Deshpande G, Rao S, Patole S. Benefits of probiotics on enteral nutrition in preterm neonates: a systematic review. Am J Clin Nutr. 2014;100(6):1508-1519.
10. Olsen R, Greisen G, Schrøder M, Brok J. Prophylactic probiotics for preterm infants: a systematic review and meta-analysis of observational studies. Neonatology. 2016;109(2):105-112.
11. Denkel LA, Schwab F, Garten L, Geffers C, Gastmeier P, Piening B. Protective effect of dual-strain probiotics in preterm infants: a multi-center time series analysis. PLoS One. 2016;11(6):e0158136.
12. Ofek Shlomai N, Deshpande G, Rao S, Patole S. Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology. 2014;105(1):64-70.
13. Deshpande G, Rao S, Patole S. Probiotics in neonatal intensive care—back to the future. Aust N Z J Obstet Gynaecol. 2015;55(3):210-217.
14. Costeloe K, Hardy P, Juszczak E, Wilks M, Millar MR. Probiotics in Preterm Infants Study Collaborative Group. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet. 2016;387(10019):649-660.
15. Modi N. Probiotics and necrotising enterocolitis: the devil (as always) is in the detail. Commentary on N Ofek Shlomai et al: “Probiotics for preterm neonates: what will it take to change clinical practice?” [Neonatology. 2014;105:64-70]. Neonatology. 2014;105(1):71-73.
16. Neu J. Probiotics and necrotizing enterocolitis. Clin Perinatol. 2014;41(4):967-978.
17. Frost BL, Modi BP, Jaksic T, Caplan MS. New medical and surgical insights into neonatal necrotizing enterocolitis: a review. JAMA Pediatr. 2017;171(1):83-88.
18. Eaton S, Rees CM, Hall NJ. Current research on the epidemiology, pathogenesis, and management of necrotizing enterocolitis. Neonatology. 2017;111(4):423-430.
19. Embleton ND, Zalewski S, Berrington JE. Probiotics for prevention of NEC and sepsis in preterm infants. Curr Opin Infect Dis. 2016;29(3):256-261.
20. Neu J. Commentary. eNeonatal Review. 2014;10(1). http://www.eneonatalreview.org/newsletters/2014/volume10_issue01.html. Published October 31, 2014.
21. Athalye-Jape G, Rao S, Patole S. Lactobacillus reuteri DSM 17938 as a probiotic for preterm neonates: a strain-specific systematic review. JPEN J Parenter Enteral Nutr. 2016;40(6):783-794.
22. Szajewska H, Guandalini S, Morelli L, Van Goudoever JB, Walker A. Effect of Bifidobacterium animalis subsp lactis supplementation in preterm infants: a systematic review of randomized controlled trials. J Pediatr Gastroenterol Nutr. 2010;51(2):203-209.
23. Patole SK, Rao SC, Keil AD, Nathan EA, Doherty DA, Simmer KN. Benefits of Bifidobacterium breve M-16V supplementation in preterm neonates—a retrospective cohort study. PLoS One. 2016;11(3):e0150775.
24. Patole S, Keil AD, Chang A, et al. Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates—a randomised double blind placebo controlled trial. PLoS One. 2014;9(3):e89511.
25. Centre for Reviews and Dissemination. CRD’s guidance for undertaking reviews in health care. http://www.york.ac.uk/inst/crd/systematic_reviews_book.htm. Accessed August 25, 2016.
26. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cambridge, UK: The Cochrane Collaboration; 2011.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
28. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
29. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179-201.
30. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
31. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables binary outcomes. J Clin Epidemiol. 2013;66:158-172.
32. Hikaru U, Koichi S, Yayoi S, et al. Bifidobacteria prevents preterm infants from developing infection and sepsis. Int J Probiotics Prebiotics. 2010;5(1):33-36.
33. Fujii T, Ohtsuka Y, Lee T, et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J Pediatr Gastroenterol Nutr. 2006;43(1):83-88.
34. Li Y, Shimizu T, Hosaka A, Kaneko N, Ohtsuka Y, Yamashiro Y. Effects of Bifidobacterium breve supplementation on intestinal flora of low birth weight infants. Pediatr Int. 2004;46(5):509-515.
35. Wang C, Shoji H, Sato H, et al. Effects of oral administration of Bifidobacterium breve on fecal lactic acid and short-chain fatty acids in low birth weight infants. J Pediatr Gastroenterol Nutr. 2007;44(2):252-257.
36. Ishizeki S, Masaoki S, Masaaki T, Tomoko Y. Effect of administration of bifidobacteria on intestinal microbiota in low-birth-weight infants and transition of administered bifidobacteria: a comparison between one species and three-species administration. Anaerobe. 2013;23:38-44.
37. Satoh Y, Shinohara K, Umezaki H, et al. Bifidobacteria prevents necrotising enterocolitis and infection. Int J Probiot Prebiot. 2007;2:149-154.
38. Umeda S, Yoshikazu S, Noriko K, Ryuichi M, Moriyasu O. Effects of probiotics for extremely low birth weight infants Neonatal Care Center, Okinawa Prefectural Chubu [hospital translation]. Journal of Japan Society of Perinatal and Neonatal Medicine. 2010;46(2):531.
39. Martin R, Jimenez E, Heilig H, et al. Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis and quantitative real-time PCR. Appl Environ Microbiol. 2009;75:965-969.
40. Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol. 1999;65(10):4506-4512.
41. Mikami K, Kimura M, Takahashi H. Influence of maternal bifidobacteria on the development of gut bifidobacteria in infants. Pharmaceuticals (Basel). 2012;5:629-642.
42. Hirosuke S, Toshitaka O, Jin-zhong X. Genotypic and phenotypic evaluation revealed the appropriateness of human-residential bifidobacteria for human use. Milk Science. 2015;64:261-269.
43. Akiyama K, Shimata Y, Ishizeki S, et al. Effects of oral administration of Bifidobacterium longum on development of intestinal microflora in extremely premature infants (comparison with Bifidobacterium breve). Acta Neonatol Jap. 1994;30:257-263.
44. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493.
45. Deshpande G, Rao S, Athalye-Jape G, Conway P, Patole S. Probiotics in very preterm infants: the PiPS trial. Lancet. 2016;388(10045):655.
46. Karthikeyan G, Bhat BV. The PiPS (Probiotics in Preterm Infants Study) Trial—controlling the confounding factor of cross-contamination unveils significant benefits. Indian Pediatr. 2017;54(2):162.
47. Totsu S, Yamasaki C, Terahara M, Uchiyama A, Kusuda S. Bifidobacterium and enteral feeding in preterm infants: cluster-randomized trial. Pediatr Int. 2014;56(5):714-719.
48. Namachivayam K, Blanco CL, MohanKumar K, et al. Smad7 inhibits autocrine expression of TGF-b2 in intestinal epithelial cells in baboon necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2013;304(2):G167-G180.
49. Satoh T, Izumi H, Iwabuchi N, et al. Bifidobacterium breve prevents necrotising enterocolitis by suppressing inflammatory responses in a preterm rat model. Benef Microbes. 2016;7(1):75-82.
50. Ohtsuka Y, Ikegami T, Izumi H, Namura M, Ikeda T. Effects of Bifidobacterium breve on inflammatory gene expression in neonatal and weaning rat intestine. Ped Res. 2012;71(1):47-53.
51. Izumi H, Minegishi M, Sato Y, Shimizu T, Sekine K, Takase M. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res. 2015;78(4):407-416.
52. Abe F, Muto M, Yaeshima T, et al. Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. Anaerobe. 2010;16(2):131-136.
53. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-681.
54. Avcin SL, Pokorn M, Kitanovski L, Premru MM, Jazbec J. Bifidobacterium breve sepsis in child with high-risk acute lymphoblastic leukemia. Emerg Infect Dis. 2015;21(9):1674-1675.
55. Nakazawa T, Kaneko K, Tkahashi H, Inoue S. Neonatal meningitis caused by Bifidobacterium breve. Brain Dev. 1996;18(2):160-162.
56. Maypro. Morinaga M-16V (Bifidobacterium breve). http://maypro.com/products/morinaga-m-16v. Accessed July 2017.
57. Kitajima H, Hirano S. Safety of Bifidobacterium breve (BBG-01) in preterm infants. Pediatr Int. 2017;59(3):328-333.